A pharmacogenomics trial initiated in Scotland is recruiting up to 4,000 patients to evaluate the clinical utility of preemptive genetic testing across 60 medications. The study, conducted in partnership with Gene By Gene and Agena Bioscience, seeks to determine whether upfront testing improves treatment outcomes compared to standard practice of reactive genetic testing. This large-scale effort aims to underpin the broader adoption of pharmacogenomics in clinical care.